359 related articles for article (PubMed ID: 21844875)
1. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
[TBL] [Abstract][Full Text] [Related]
3. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
[TBL] [Abstract][Full Text] [Related]
4. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.
Vercauteren S; Zapf R; Sutherland H
Cytotherapy; 2007; 9(2):194-204. PubMed ID: 17453971
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic transplantation of CD34+ cord blood stem cells into newborn and adult NOD/SCID mice induce differential organ engraftment.
Wulf-Goldenberg A; Keil M; Fichtner I; Eckert K
Tissue Cell; 2012 Apr; 44(2):80-6. PubMed ID: 22197619
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
7. Fusion of dendritic cells and CD34+CD38- acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction.
Lei Z; Zhang GM; Hong M; Feng ZH; Huang B
J Immunother; 2009 May; 32(4):408-14. PubMed ID: 19342964
[TBL] [Abstract][Full Text] [Related]
8. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model.
Canale S; Cocco C; Frasson C; Seganfreddo E; Di Carlo E; Ognio E; Sorrentino C; Ribatti D; Zorzoli A; Basso G; Dufour C; Airoldi I
Leukemia; 2011 Dec; 25(12):1815-24. PubMed ID: 21701492
[TBL] [Abstract][Full Text] [Related]
10. Angiocidin induces differentiation of acute myeloid leukemia cells.
Tuszynski GP; Rothman VL
Exp Mol Pathol; 2013 Dec; 95(3):249-54. PubMed ID: 24036285
[TBL] [Abstract][Full Text] [Related]
11. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
12. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
13. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
14. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
[TBL] [Abstract][Full Text] [Related]
15. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of human acute myeloid leukemia cell growth by IL-12.
Ferretti E; Di Carlo E; Cocco C; Ribatti D; Sorrentino C; Ognio E; Montagna D; Pistoia V; Airoldi I
Immunol Lett; 2010 Oct; 133(2):99-105. PubMed ID: 20705102
[TBL] [Abstract][Full Text] [Related]
17. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
[TBL] [Abstract][Full Text] [Related]
18. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
[TBL] [Abstract][Full Text] [Related]
19. Functional differences between subpopulations of mobilized peripheral blood-derived CD34+ cells expressing different levels of HLA-DR, CD33, CD38 and c-kit antigens.
Sakabe H; Ohmizono Y; Tanimukai S; Kimura T; Mori KJ; Abe T; Sonoda Y
Stem Cells; 1997; 15(1):73-81. PubMed ID: 9007225
[TBL] [Abstract][Full Text] [Related]
20. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
